F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comSun Pharmaceutical Industries Ltd is India’s largest pharmaceutical company and one of the leading specialty generic drug manufacturers globally. With a strong presence in the US, India, and emerging markets, the company has built a diversified portfolio across specialty medicines, generics, APIs, and over-the-counter products.
Backed by consistent earnings growth, global expansion, and strong institutional participation, Sun Pharma remains a key defensive stock in India’s healthcare sector. In this article, we analyze Sun Pharmaceutical Industries Ltd share price targets from 2026 to 2030 using current market data, financial indicators, and long-term sector outlook.
| Detail | Value |
|---|---|
| Open | ₹1,764.20 |
| Previous Close | ₹1,764.20 |
| Day’s High | ₹1,789.90 |
| Day’s Low | ₹1,760.30 |
| VWAP | ₹1,775.84 |
| 52-Week High | ₹1,851.20 |
| 52-Week Low | ₹1,548.00 |
| All-Time High | ₹1,960.35 |
| All-Time Low | ₹7.15 |
| Market Capitalization | ₹4,26,025 Cr |
| Volume | 9,61,497 |
| Value (Lacs) | 17,072.34 |
| 20D Avg Volume | 25,05,496 |
| 20D Avg Delivery (%) | 61.27% |
| Face Value | ₹1 |
| Book Value Per Share | ₹338.51 |
| Dividend Yield | 0.90% |
| Beta | 0.74 |
| UC Limit | ₹1,940.60 |
| LC Limit | ₹1,587.80 |
The stock is trading close to its 52-week high, reflecting sustained investor confidence. A beta of 0.74 indicates lower volatility compared to the broader market, making it relatively defensive.
Sun Pharma operates across multiple segments:
Branded generics (India and emerging markets)
US generics
Specialty medicines (dermatology, ophthalmology, oncology)
Active Pharmaceutical Ingredients (APIs)
Over-the-counter (OTC) products
The company’s global presence and strong R&D capabilities allow it to maintain leadership in high-margin specialty therapies.
India’s largest pharma company by revenue
Strong US and global market exposure
Focus on specialty and high-margin products
Healthy promoter holding of 54.48%
Strong institutional participation
Defensive nature with Beta 0.74
| Investor Type | Holding (%) |
|---|---|
| Promoters | 54.48% |
| Foreign Institutions | 16.12% |
| Mutual Funds | 12.09% |
| Other Domestic Institutions | 8.73% |
| Retail & Others | 8.58% |
Strong promoter and institutional holdings reflect long-term confidence in the company’s growth strategy.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 1,950 | 2,100 |
| 2027 | 2,150 | 2,350 |
| 2028 | 2,350 | 2,600 |
| 2029 | 2,600 | 2,900 |
| 2030 | 2,900 | 3,250 |
These projections factor in specialty drug growth, strong domestic branded generics performance, global expansion, and stable healthcare demand.
By 2026, earnings growth may be driven by specialty portfolio expansion and stable US generics performance.
Growth Drivers:
Strong domestic branded generics sales
Growth in specialty therapies
Stable US market recovery
Improved operating margins
Investment View: Suitable for medium-term investors seeking defensive growth in healthcare.
By 2027, specialty products may contribute a larger share of revenue.
Growth Drivers:
Increasing global specialty drug approvals
Expansion into new therapeutic areas
Better pricing power in India
Operational efficiency improvements
Investment View: Attractive for long-term investors seeking stable returns with moderate risk.
2028 could reflect steady double-digit earnings growth supported by global demand.
Growth Drivers:
Strong R&D pipeline
Growth in emerging markets
Higher contribution from innovative therapies
Strong cash flow generation
Investment View: Balanced risk-reward opportunity with consistent compounding potential.
By 2029, Sun Pharma may strengthen its global leadership in specialty generics.
Growth Drivers:
Expansion in high-margin segments
Improved EBITDA margins
Increased institutional participation
Defensive demand for healthcare products
Investment View: Suitable for investors looking for steady, long-term capital appreciation.
By 2030, the company may solidify its position among global pharma leaders.
Growth Drivers:
Sustainable healthcare demand globally
Strong global distribution network
Consistent innovation pipeline
Stable dividend payout
Investment View: Ideal for long-term wealth creation with lower volatility compared to cyclical sectors.
Sun Pharma offers:
Defensive business model
Strong global footprint
Stable promoter and institutional backing
Moderate dividend yield (0.90%)
Lower beta (0.74) compared to broader markets
US regulatory scrutiny and pricing pressure
Currency fluctuations
R&D pipeline risks
Global competition in generics
Investors should monitor USFDA updates, specialty product performance, and quarterly earnings before making significant investment decisions.
Sun Pharmaceutical Industries Ltd remains one of India’s strongest healthcare companies with global reach and consistent profitability. Trading near its 52-week high, the stock reflects strong institutional confidence and defensive stability.
Based on current data and sector outlook, the stock could potentially reach ₹2,900 to ₹3,250 by 2030, supported by specialty drug expansion, global demand, and operational strength.
For investors seeking long-term exposure to India’s pharmaceutical sector with moderate volatility, Sun Pharmaceutical Industries Ltd appears well-positioned for steady growth.
1. What is the current share price of Sun Pharmaceutical Industries Ltd?
It is trading around ₹1,764 based on the latest market data.
2. What is the 2026 share price target?
The expected range is ₹1,950 to ₹2,100.
3. Is Sun Pharma a good long-term investment?
Yes, especially for investors seeking defensive healthcare exposure with stable growth.
4. What is the 2030 share price target?
The projected range for 2030 is ₹2,900 to ₹3,250.
5. Why is Sun Pharma considered defensive?
Because healthcare demand remains stable across economic cycles, and the stock has a lower beta (0.74), indicating relatively lower volatility.
Disclaimer: This article is for educational purposes only. Stock market investments are subject to market risks. Please consult a financial advisor before making investment decisions.
Register & Login